nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—SRD5A1—Androgen biosynthesis—HSD17B12—peripheral nervous system neoplasm	0.077	0.341	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of steroid hormones and vitamin D—HSD17B12—peripheral nervous system neoplasm	0.032	0.142	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of steroid hormones and vitamin D—HSD17B12—peripheral nervous system neoplasm	0.00694	0.0308	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.00328	0.0145	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.00307	0.0136	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—COX2—peripheral nervous system neoplasm	0.00265	0.0117	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.0025	0.0111	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—NTS—peripheral nervous system neoplasm	0.00246	0.0109	CbGpPWpGaD
Levonorgestrel—SHBG—Nongenotropic Androgen signaling—HRAS—peripheral nervous system neoplasm	0.00238	0.0105	CbGpPWpGaD
Levonorgestrel—ESR1—Estrogen signaling pathway—GNAS—peripheral nervous system neoplasm	0.00236	0.0104	CbGpPWpGaD
Levonorgestrel—CYP19A1—FSH signaling pathway—BDNF—peripheral nervous system neoplasm	0.00231	0.0102	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.00216	0.00957	CbGpPWpGaD
Levonorgestrel—SHBG—Nongenotropic Androgen signaling—AKT1—peripheral nervous system neoplasm	0.0021	0.00931	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—NF1—peripheral nervous system neoplasm	0.00205	0.00909	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—BARD1—peripheral nervous system neoplasm	0.00203	0.009	CbGpPWpGaD
Levonorgestrel—PGR—Nuclear signaling by ERBB4—PTPN11—peripheral nervous system neoplasm	0.00183	0.0081	CbGpPWpGaD
Levonorgestrel—CYP3A4—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.00175	0.00777	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—BARD1—peripheral nervous system neoplasm	0.00175	0.00775	CbGpPWpGaD
Levonorgestrel—ESR1—FOXM1 transcription factor network—CHEK2—peripheral nervous system neoplasm	0.00174	0.00771	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—BARD1—peripheral nervous system neoplasm	0.00157	0.00694	CbGpPWpGaD
Levonorgestrel—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.00149	0.0066	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.00146	0.00646	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—IFNB1—peripheral nervous system neoplasm	0.00138	0.00611	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.00137	0.00608	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—TH—peripheral nervous system neoplasm	0.00136	0.00602	CbGpPWpGaD
Levonorgestrel—ESR1—FOXM1 transcription factor network—BIRC5—peripheral nervous system neoplasm	0.00126	0.00559	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—NF1—peripheral nervous system neoplasm	0.00126	0.00556	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.00121	0.00537	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—TH—peripheral nervous system neoplasm	0.00119	0.00525	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—NF1—peripheral nervous system neoplasm	0.00108	0.00479	CbGpPWpGaD
Levonorgestrel—ESR1—Nuclear signaling by ERBB4—PTPN11—peripheral nervous system neoplasm	0.00107	0.00476	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—IFNB1—peripheral nervous system neoplasm	0.00106	0.00471	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.00106	0.00468	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—GNS—peripheral nervous system neoplasm	0.00106	0.00467	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—NME1—peripheral nervous system neoplasm	0.00101	0.00448	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—COX2—peripheral nervous system neoplasm	0.000974	0.00431	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—NF1—peripheral nervous system neoplasm	0.000967	0.00428	CbGpPWpGaD
Levonorgestrel—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.00096	0.00425	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—AURKA—peripheral nervous system neoplasm	0.000908	0.00402	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000885	0.00392	CbGpPWpGaD
Levonorgestrel—ESR1—FOXM1 transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.000836	0.0037	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000812	0.0036	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.00081	0.00359	CbGpPWpGaD
Levonorgestrel—AR—Coregulation of Androgen receptor activity—CDKN2A—peripheral nervous system neoplasm	0.000805	0.00357	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—AURKA—peripheral nervous system neoplasm	0.000781	0.00346	CbGpPWpGaD
Levonorgestrel—AR—Nongenotropic Androgen signaling—HRAS—peripheral nervous system neoplasm	0.000737	0.00326	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000712	0.00315	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—AURKA—peripheral nervous system neoplasm	0.000699	0.0031	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000699	0.00309	CbGpPWpGaD
Levonorgestrel—PGR—Validated nuclear estrogen receptor alpha network—MYC—peripheral nervous system neoplasm	0.000689	0.00305	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000673	0.00298	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.00066	0.00292	CbGpPWpGaD
Levonorgestrel—AR—Nongenotropic Androgen signaling—AKT1—peripheral nervous system neoplasm	0.00065	0.00288	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—peripheral nervous system neoplasm	0.000648	0.00287	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—ENO2—peripheral nervous system neoplasm	0.000639	0.00283	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—PTPN11—peripheral nervous system neoplasm	0.000636	0.00282	CbGpPWpGaD
Levonorgestrel—ESR1—Estrogen signaling pathway—AKT1—peripheral nervous system neoplasm	0.000636	0.00282	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000625	0.00277	CbGpPWpGaD
Levonorgestrel—CYP19A1—FSH signaling pathway—AKT1—peripheral nervous system neoplasm	0.000625	0.00277	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—EED—peripheral nervous system neoplasm	0.000622	0.00275	CbGpPWpGaD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—NRAS—peripheral nervous system neoplasm	0.00062	0.00275	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—PTPN11—peripheral nervous system neoplasm	0.000616	0.00273	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.000613	0.00272	CbGpPWpGaD
Levonorgestrel—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000579	0.00256	CbGpPWpGaD
Levonorgestrel—ESR1—FOXM1 transcription factor network—MYC—peripheral nervous system neoplasm	0.000567	0.00251	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	0.000566	0.00251	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	0.000561	0.00249	CbGpPWpGaD
Levonorgestrel—ESR1—LKB1 signaling events—MYC—peripheral nervous system neoplasm	0.000556	0.00246	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.000556	0.00246	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	0.000552	0.00245	CbGpPWpGaD
Levonorgestrel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000552	0.00244	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—BCHE—peripheral nervous system neoplasm	0.00054	0.00239	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—peripheral nervous system neoplasm	0.000538	0.00239	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	0.000527	0.00233	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000518	0.0023	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000515	0.00228	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—TH—peripheral nervous system neoplasm	0.000508	0.00225	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—ERBB2—peripheral nervous system neoplasm	0.000503	0.00223	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—SUZ12—peripheral nervous system neoplasm	0.000497	0.0022	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—ERBB2—peripheral nervous system neoplasm	0.000487	0.00216	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—EED—peripheral nervous system neoplasm	0.000474	0.0021	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.000472	0.00209	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000469	0.00208	CbGpPWpGaD
Levonorgestrel—ESR1—LKB1 signaling events—TP53—peripheral nervous system neoplasm	0.000457	0.00202	CbGpPWpGaD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—HRAS—peripheral nervous system neoplasm	0.000454	0.00201	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—peripheral nervous system neoplasm	0.000439	0.00195	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—MYC—peripheral nervous system neoplasm	0.000435	0.00193	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	0.000433	0.00192	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	0.000425	0.00188	CbGpPWpGaD
Levonorgestrel—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000416	0.000537	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—GNAS—peripheral nervous system neoplasm	0.000415	0.00184	CbGpPWpGaD
Levonorgestrel—Rash—Melphalan—peripheral nervous system neoplasm	0.000415	0.000536	CcSEcCtD
Levonorgestrel—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000414	0.000535	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	0.000414	0.00183	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000413	0.000534	CcSEcCtD
Levonorgestrel—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.000412	0.000532	CcSEcCtD
Levonorgestrel—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000411	0.000531	CcSEcCtD
Levonorgestrel—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.00041	0.00053	CcSEcCtD
Levonorgestrel—Migraine—Doxorubicin—peripheral nervous system neoplasm	0.000409	0.000529	CcSEcCtD
Levonorgestrel—Affect lability—Doxorubicin—peripheral nervous system neoplasm	0.000409	0.000529	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000408	0.000528	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000407	0.0018	CbGpPWpGaD
Levonorgestrel—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000406	0.000525	CcSEcCtD
Levonorgestrel—Breast disorder—Epirubicin—peripheral nervous system neoplasm	0.000406	0.000525	CcSEcCtD
Levonorgestrel—ESR1—Validated nuclear estrogen receptor alpha network—MYC—peripheral nervous system neoplasm	0.000405	0.00179	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000401	0.000519	CcSEcCtD
Levonorgestrel—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000401	0.000518	CcSEcCtD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—AKT1—peripheral nervous system neoplasm	0.000401	0.00177	CbGpPWpGaD
Levonorgestrel—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000399	0.000516	CcSEcCtD
Levonorgestrel—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000399	0.000516	CcSEcCtD
Levonorgestrel—Nausea—Topotecan—peripheral nervous system neoplasm	0.000399	0.000516	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000398	0.000514	CcSEcCtD
Levonorgestrel—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000396	0.000511	CcSEcCtD
Levonorgestrel—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000396	0.000511	CcSEcCtD
Levonorgestrel—Mood swings—Doxorubicin—peripheral nervous system neoplasm	0.000394	0.000509	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000392	0.000507	CcSEcCtD
Levonorgestrel—Infection—Etoposide—peripheral nervous system neoplasm	0.000391	0.000506	CcSEcCtD
Levonorgestrel—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	0.000391	0.000505	CcSEcCtD
Levonorgestrel—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000391	0.000505	CcSEcCtD
Levonorgestrel—Nausea—Melphalan—peripheral nervous system neoplasm	0.000391	0.000505	CcSEcCtD
Levonorgestrel—Influenza—Epirubicin—peripheral nervous system neoplasm	0.000388	0.000502	CcSEcCtD
Levonorgestrel—Asthma—Epirubicin—peripheral nervous system neoplasm	0.000388	0.000502	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—MYC—peripheral nervous system neoplasm	0.000385	0.00171	CbGpPWpGaD
Levonorgestrel—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000385	0.000497	CcSEcCtD
Levonorgestrel—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000385	0.000497	CcSEcCtD
Levonorgestrel—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000383	0.000496	CcSEcCtD
Levonorgestrel—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000383	0.000495	CcSEcCtD
Levonorgestrel—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000381	0.000493	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000381	0.000492	CcSEcCtD
Levonorgestrel—AR—Gene Expression—SUZ12—peripheral nervous system neoplasm	0.000379	0.00168	CbGpPWpGaD
Levonorgestrel—AR—Coregulation of Androgen receptor activity—AKT1—peripheral nervous system neoplasm	0.000378	0.00168	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—MYC—peripheral nervous system neoplasm	0.000377	0.00167	CbGpPWpGaD
Levonorgestrel—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.000376	0.000486	CcSEcCtD
Levonorgestrel—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000376	0.000486	CcSEcCtD
Levonorgestrel—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000374	0.000483	CcSEcCtD
Levonorgestrel—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000374	0.000483	CcSEcCtD
Levonorgestrel—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000373	0.000482	CcSEcCtD
Levonorgestrel—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000372	0.000481	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000371	0.00048	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—NRAS—peripheral nervous system neoplasm	0.00037	0.00164	CbGpPWpGaD
Levonorgestrel—Pain—Cisplatin—peripheral nervous system neoplasm	0.000368	0.000475	CcSEcCtD
Levonorgestrel—ESR1—Gene Expression—EED—peripheral nervous system neoplasm	0.000365	0.00162	CbGpPWpGaD
Levonorgestrel—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000363	0.00047	CcSEcCtD
Levonorgestrel—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000362	0.000468	CcSEcCtD
Levonorgestrel—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.000362	0.000468	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—PTPN11—peripheral nervous system neoplasm	0.000362	0.0016	CbGpPWpGaD
Levonorgestrel—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000361	0.000467	CcSEcCtD
Levonorgestrel—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000359	0.000465	CcSEcCtD
Levonorgestrel—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.000359	0.000465	CcSEcCtD
Levonorgestrel—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000359	0.000464	CcSEcCtD
Levonorgestrel—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000358	0.000463	CcSEcCtD
Levonorgestrel—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000357	0.000462	CcSEcCtD
Levonorgestrel—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000353	0.000457	CcSEcCtD
Levonorgestrel—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000351	0.000454	CcSEcCtD
Levonorgestrel—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000351	0.000454	CcSEcCtD
Levonorgestrel—Somnolence—Etoposide—peripheral nervous system neoplasm	0.00035	0.000453	CcSEcCtD
Levonorgestrel—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000349	0.000451	CcSEcCtD
Levonorgestrel—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000348	0.00045	CcSEcCtD
Levonorgestrel—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000346	0.000448	CcSEcCtD
Levonorgestrel—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000346	0.000448	CcSEcCtD
Levonorgestrel—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000346	0.000447	CcSEcCtD
Levonorgestrel—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000346	0.000447	CcSEcCtD
Levonorgestrel—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000345	0.000446	CcSEcCtD
Levonorgestrel—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000343	0.000444	CcSEcCtD
Levonorgestrel—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000343	0.000443	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.00034	0.00044	CcSEcCtD
Levonorgestrel—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.00034	0.00044	CcSEcCtD
Levonorgestrel—Fatigue—Etoposide—peripheral nervous system neoplasm	0.00034	0.000439	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000339	0.0015	CbGpPWpGaD
Levonorgestrel—Pain—Etoposide—peripheral nervous system neoplasm	0.000337	0.000436	CcSEcCtD
Levonorgestrel—Constipation—Etoposide—peripheral nervous system neoplasm	0.000337	0.000436	CcSEcCtD
Levonorgestrel—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000337	0.000435	CcSEcCtD
Levonorgestrel—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000336	0.000434	CcSEcCtD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—peripheral nervous system neoplasm	0.000335	0.00148	CbGpPWpGaD
Levonorgestrel—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000334	0.000432	CcSEcCtD
Levonorgestrel—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000334	0.000432	CcSEcCtD
Levonorgestrel—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000333	0.00043	CcSEcCtD
Levonorgestrel—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000332	0.000429	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.00033	0.00146	CbGpPWpGaD
Levonorgestrel—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000327	0.000423	CcSEcCtD
Levonorgestrel—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000325	0.00042	CcSEcCtD
Levonorgestrel—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000325	0.00042	CcSEcCtD
Levonorgestrel—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000323	0.000418	CcSEcCtD
Levonorgestrel—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000322	0.000417	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000322	0.000417	CcSEcCtD
Levonorgestrel—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000322	0.000416	CcSEcCtD
Levonorgestrel—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000321	0.000415	CcSEcCtD
Levonorgestrel—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.00032	0.000414	CcSEcCtD
Levonorgestrel—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.00032	0.000414	CcSEcCtD
Levonorgestrel—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000318	0.000411	CcSEcCtD
Levonorgestrel—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000318	0.000411	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000317	0.0014	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000317	0.00041	CcSEcCtD
Levonorgestrel—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000316	0.000409	CcSEcCtD
Levonorgestrel—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000313	0.000405	CcSEcCtD
Levonorgestrel—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000312	0.000404	CcSEcCtD
Levonorgestrel—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000312	0.000403	CcSEcCtD
Levonorgestrel—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000311	0.000403	CcSEcCtD
Levonorgestrel—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000311	0.000403	CcSEcCtD
Levonorgestrel—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000311	0.000403	CcSEcCtD
Levonorgestrel—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000311	0.000402	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000309	0.0004	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—TP53—peripheral nervous system neoplasm	0.000309	0.00137	CbGpPWpGaD
Levonorgestrel—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000309	0.0004	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	0.000309	0.00137	CbGpPWpGaD
Levonorgestrel—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000309	0.000399	CcSEcCtD
Levonorgestrel—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000309	0.000399	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000307	0.000397	CcSEcCtD
Levonorgestrel—Rash—Vincristine—peripheral nervous system neoplasm	0.000307	0.000396	CcSEcCtD
Levonorgestrel—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000306	0.000396	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000306	0.000395	CcSEcCtD
Levonorgestrel—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000305	0.000394	CcSEcCtD
Levonorgestrel—Headache—Vincristine—peripheral nervous system neoplasm	0.000305	0.000394	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—peripheral nervous system neoplasm	0.000302	0.00134	CbGpPWpGaD
Levonorgestrel—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000301	0.000389	CcSEcCtD
Levonorgestrel—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.0003	0.000388	CcSEcCtD
Levonorgestrel—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.0003	0.000387	CcSEcCtD
Levonorgestrel—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000294	0.00038	CcSEcCtD
Levonorgestrel—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000294	0.00038	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000292	0.00129	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—SUZ12—peripheral nervous system neoplasm	0.000292	0.00129	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000291	0.00129	CbGpPWpGaD
Levonorgestrel—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000291	0.000376	CcSEcCtD
Levonorgestrel—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.00029	0.000375	CcSEcCtD
Levonorgestrel—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000289	0.000374	CcSEcCtD
Levonorgestrel—Nausea—Vincristine—peripheral nervous system neoplasm	0.000289	0.000373	CcSEcCtD
Levonorgestrel—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000289	0.000373	CcSEcCtD
Levonorgestrel—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000288	0.000373	CcSEcCtD
Levonorgestrel—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000288	0.000372	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000286	0.00037	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—ERBB2—peripheral nervous system neoplasm	0.000286	0.00127	CbGpPWpGaD
Levonorgestrel—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000285	0.000369	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000284	0.000367	CcSEcCtD
Levonorgestrel—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000283	0.000365	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000283	0.000365	CcSEcCtD
Levonorgestrel—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000282	0.000365	CcSEcCtD
Levonorgestrel—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000281	0.000363	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000281	0.00124	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.00028	0.00124	CbGpPWpGaD
Levonorgestrel—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.00028	0.000362	CcSEcCtD
Levonorgestrel—ESR1—Leptin signaling pathway—HRAS—peripheral nervous system neoplasm	0.00028	0.00124	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—AKT1—peripheral nervous system neoplasm	0.00028	0.00124	CbGpPWpGaD
Levonorgestrel—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000279	0.00036	CcSEcCtD
Levonorgestrel—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000278	0.000359	CcSEcCtD
Levonorgestrel—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000277	0.000358	CcSEcCtD
Levonorgestrel—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000275	0.000355	CcSEcCtD
Levonorgestrel—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000273	0.000354	CcSEcCtD
Levonorgestrel—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000272	0.000352	CcSEcCtD
Levonorgestrel—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000272	0.000352	CcSEcCtD
Levonorgestrel—Rash—Cisplatin—peripheral nervous system neoplasm	0.000271	0.000351	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	0.000271	0.0012	CbGpPWpGaD
Levonorgestrel—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000271	0.00035	CcSEcCtD
Levonorgestrel—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000271	0.00035	CcSEcCtD
Levonorgestrel—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000271	0.00035	CcSEcCtD
Levonorgestrel—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.00027	0.000349	CcSEcCtD
Levonorgestrel—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000269	0.000348	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—AKT1—peripheral nervous system neoplasm	0.000267	0.00118	CbGpPWpGaD
Levonorgestrel—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000267	0.000345	CcSEcCtD
Levonorgestrel—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000267	0.000345	CcSEcCtD
Levonorgestrel—Tension—Epirubicin—peripheral nervous system neoplasm	0.000266	0.000343	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000264	0.00117	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000263	0.00117	CbGpPWpGaD
Levonorgestrel—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000263	0.00034	CcSEcCtD
Levonorgestrel—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000262	0.000338	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000261	0.00116	CbGpPWpGaD
Levonorgestrel—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000261	0.000337	CcSEcCtD
Levonorgestrel—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.00026	0.000336	CcSEcCtD
Levonorgestrel—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.00026	0.000336	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000259	0.000335	CcSEcCtD
Levonorgestrel—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000257	0.000332	CcSEcCtD
Levonorgestrel—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000255	0.00033	CcSEcCtD
Levonorgestrel—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000254	0.000329	CcSEcCtD
Levonorgestrel—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000252	0.000326	CcSEcCtD
Levonorgestrel—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000251	0.000324	CcSEcCtD
Levonorgestrel—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.00025	0.000324	CcSEcCtD
Levonorgestrel—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.00025	0.000324	CcSEcCtD
Levonorgestrel—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.00025	0.000323	CcSEcCtD
Levonorgestrel—Rash—Etoposide—peripheral nervous system neoplasm	0.000248	0.000321	CcSEcCtD
Levonorgestrel—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000248	0.000321	CcSEcCtD
Levonorgestrel—ESR1—Leptin signaling pathway—AKT1—peripheral nervous system neoplasm	0.000247	0.00109	CbGpPWpGaD
Levonorgestrel—Headache—Etoposide—peripheral nervous system neoplasm	0.000247	0.000319	CcSEcCtD
Levonorgestrel—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000247	0.000319	CcSEcCtD
Levonorgestrel—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000246	0.000318	CcSEcCtD
Levonorgestrel—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000243	0.000314	CcSEcCtD
Levonorgestrel—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000243	0.000314	CcSEcCtD
Levonorgestrel—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000243	0.000314	CcSEcCtD
Levonorgestrel—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000242	0.000313	CcSEcCtD
Levonorgestrel—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000241	0.000311	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	0.000239	0.00106	CbGpPWpGaD
Levonorgestrel—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000239	0.000309	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	0.000238	0.00105	CbGpPWpGaD
Levonorgestrel—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000238	0.000307	CcSEcCtD
Levonorgestrel—Cough—Epirubicin—peripheral nervous system neoplasm	0.000236	0.000305	CcSEcCtD
Levonorgestrel—Nausea—Etoposide—peripheral nervous system neoplasm	0.000234	0.000303	CcSEcCtD
Levonorgestrel—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000234	0.000302	CcSEcCtD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—peripheral nervous system neoplasm	0.000232	0.00103	CbGpPWpGaD
Levonorgestrel—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000231	0.000299	CcSEcCtD
Levonorgestrel—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.00023	0.000298	CcSEcCtD
Levonorgestrel—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.00023	0.000298	CcSEcCtD
Levonorgestrel—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.00023	0.000297	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—GNS—peripheral nervous system neoplasm	0.000229	0.00102	CbGpPWpGaD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000229	0.000296	CcSEcCtD
Levonorgestrel—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000228	0.000294	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000227	0.00101	CbGpPWpGaD
Levonorgestrel—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000225	0.000291	CcSEcCtD
Levonorgestrel—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000225	0.00029	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000222	0.000981	CbGpPWpGaD
Levonorgestrel—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000221	0.000286	CcSEcCtD
Levonorgestrel—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000221	0.000286	CcSEcCtD
Levonorgestrel—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.00022	0.000285	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—NME1—peripheral nervous system neoplasm	0.00022	0.000973	CbGpPWpGaD
Levonorgestrel—Infection—Epirubicin—peripheral nervous system neoplasm	0.000219	0.000284	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000219	0.00097	CbGpPWpGaD
Levonorgestrel—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000219	0.000282	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—NRAS—peripheral nervous system neoplasm	0.000217	0.000963	CbGpPWpGaD
Levonorgestrel—Shock—Epirubicin—peripheral nervous system neoplasm	0.000217	0.000281	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000217	0.000961	CbGpPWpGaD
Levonorgestrel—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000217	0.00028	CcSEcCtD
Levonorgestrel—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000216	0.000279	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000216	0.000957	CbGpPWpGaD
Levonorgestrel—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000215	0.000277	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000214	0.000276	CcSEcCtD
Levonorgestrel—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000213	0.000276	CcSEcCtD
Levonorgestrel—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000213	0.000276	CcSEcCtD
Levonorgestrel—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.000275	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.000274	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—COX2—peripheral nervous system neoplasm	0.000211	0.000937	CbGpPWpGaD
Levonorgestrel—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000211	0.000272	CcSEcCtD
Levonorgestrel—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000211	0.000272	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000204	0.000905	CbGpPWpGaD
Levonorgestrel—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000204	0.000264	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000204	0.000902	CbGpPWpGaD
Levonorgestrel—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000203	0.000262	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000201	0.00026	CcSEcCtD
Levonorgestrel—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000201	0.00026	CcSEcCtD
Levonorgestrel—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.0002	0.000259	CcSEcCtD
Levonorgestrel—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.0002	0.000258	CcSEcCtD
Levonorgestrel—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000257	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000198	0.000255	CcSEcCtD
Levonorgestrel—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000197	0.000255	CcSEcCtD
Levonorgestrel—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000196	0.000254	CcSEcCtD
Levonorgestrel—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000195	0.000252	CcSEcCtD
Levonorgestrel—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000194	0.000251	CcSEcCtD
Levonorgestrel—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000192	0.000248	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000191	0.000247	CcSEcCtD
Levonorgestrel—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.00019	0.000246	CcSEcCtD
Levonorgestrel—Pain—Epirubicin—peripheral nervous system neoplasm	0.000189	0.000244	CcSEcCtD
Levonorgestrel—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000189	0.000244	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000187	0.000827	CbGpPWpGaD
Levonorgestrel—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.000241	CcSEcCtD
Levonorgestrel—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000185	0.000239	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000183	0.000812	CbGpPWpGaD
Levonorgestrel—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000182	0.000236	CcSEcCtD
Levonorgestrel—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000182	0.000235	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000181	0.000233	CcSEcCtD
Levonorgestrel—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.00018	0.000233	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	0.00018	0.000797	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000178	0.00023	CcSEcCtD
Levonorgestrel—Ethinyl Estradiol—ABCB1—peripheral nervous system neoplasm	0.000177	0.267	CrCbGaD
Levonorgestrel—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000176	0.000228	CcSEcCtD
Levonorgestrel—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000176	0.000228	CcSEcCtD
Levonorgestrel—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000175	0.000227	CcSEcCtD
Levonorgestrel—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.000226	CcSEcCtD
Levonorgestrel—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.000226	CcSEcCtD
Levonorgestrel—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000175	0.000226	CcSEcCtD
Levonorgestrel—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000175	0.000226	CcSEcCtD
Levonorgestrel—ESR1—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000172	0.00076	CbGpPWpGaD
Levonorgestrel—Norethindrone—ABCB1—peripheral nervous system neoplasm	0.000171	0.257	CrCbGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000169	0.000747	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000167	0.000741	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000167	0.000216	CcSEcCtD
Levonorgestrel—ESR1—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000164	0.000728	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000163	0.00021	CcSEcCtD
Levonorgestrel—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.00021	CcSEcCtD
Levonorgestrel—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.000209	CcSEcCtD
Levonorgestrel—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.000209	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	0.000159	0.000705	CbGpPWpGaD
Levonorgestrel—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000205	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000158	0.000699	CbGpPWpGaD
Levonorgestrel—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000156	0.000202	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000154	0.00068	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000152	0.000673	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000195	CcSEcCtD
Levonorgestrel—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000151	0.000195	CcSEcCtD
Levonorgestrel—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.00019	CcSEcCtD
Levonorgestrel—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000189	CcSEcCtD
Levonorgestrel—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.000187	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	0.000143	0.000632	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000141	0.000625	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	0.00014	0.000622	CbGpPWpGaD
Levonorgestrel—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000182	CcSEcCtD
Levonorgestrel—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000181	CcSEcCtD
Levonorgestrel—Rash—Epirubicin—peripheral nervous system neoplasm	0.000139	0.00018	CcSEcCtD
Levonorgestrel—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000139	0.00018	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—ENO2—peripheral nervous system neoplasm	0.000139	0.000615	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000139	0.000614	CbGpPWpGaD
Levonorgestrel—Headache—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000179	CcSEcCtD
Levonorgestrel—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000137	0.000607	CbGpPWpGaD
Levonorgestrel—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000175	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000131	0.000582	CbGpPWpGaD
Levonorgestrel—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000131	0.00017	CcSEcCtD
Levonorgestrel—ESR1—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.00013	0.000576	CbGpPWpGaD
Levonorgestrel—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000168	CcSEcCtD
Levonorgestrel—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000167	CcSEcCtD
Levonorgestrel—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000166	CcSEcCtD
Levonorgestrel—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000166	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000125	0.000554	CbGpPWpGaD
Levonorgestrel—Hydrocortisone—ABCB1—peripheral nervous system neoplasm	0.000122	0.184	CrCbGaD
Levonorgestrel—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000157	CcSEcCtD
Levonorgestrel—ESR1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.00012	0.000531	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—BCHE—peripheral nervous system neoplasm	0.000117	0.00052	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000117	0.000518	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000115	0.000509	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—AKT1—peripheral nervous system neoplasm	0.000112	0.000496	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000112	0.000496	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—TH—peripheral nervous system neoplasm	0.00011	0.000489	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	0.000109	0.000482	CbGpPWpGaD
Levonorgestrel—Progesterone—ABCB1—peripheral nervous system neoplasm	9.94e-05	0.15	CrCbGaD
Levonorgestrel—Testosterone—ABCB1—peripheral nervous system neoplasm	9.4e-05	0.142	CrCbGaD
Levonorgestrel—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	9.25e-05	0.00041	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	9.01e-05	0.000399	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GNAS—peripheral nervous system neoplasm	9e-05	0.000399	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ABCB1—peripheral nervous system neoplasm	8.84e-05	0.000391	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	8.38e-05	0.000371	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.98e-05	0.000354	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	7.71e-05	0.000341	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	7.35e-05	0.000325	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—MYC—peripheral nervous system neoplasm	6.87e-05	0.000305	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	6.74e-05	0.000299	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	6.69e-05	0.000296	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	6.41e-05	0.000284	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.31e-05	0.000279	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	6.17e-05	0.000273	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.73e-05	0.000254	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—MYC—peripheral nervous system neoplasm	5.24e-05	0.000232	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.8e-05	0.000213	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—AKT1—peripheral nervous system neoplasm	4.77e-05	0.000211	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.68e-05	0.000207	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.47e-05	0.000198	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	4.05e-05	0.000179	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—MYC—peripheral nervous system neoplasm	4.03e-05	0.000179	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.7e-05	0.000164	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.67e-05	0.000163	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—AKT1—peripheral nervous system neoplasm	3.63e-05	0.000161	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.51e-05	0.000156	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	3.42e-05	0.000152	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.36e-05	0.000149	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.27e-05	0.000145	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	3.22e-05	0.000143	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.1e-05	0.000137	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.82e-05	0.000125	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—AKT1—peripheral nervous system neoplasm	2.8e-05	0.000124	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	2.63e-05	0.000116	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.62e-05	0.000116	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	2.58e-05	0.000114	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—AKT1—peripheral nervous system neoplasm	2.43e-05	0.000108	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.15e-05	9.54e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.06e-05	9.13e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.82e-05	8.06e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	7.09e-06	3.14e-05	CbGpPWpGaD
